Lyell Immunopharma (NASDAQ:LYEL) Price Target Cut to $6.00 by Analysts at Bank of America

Lyell Immunopharma (NASDAQ:LYEL) had its target price lowered by Bank of America from $9.00 to $6.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reissued a neutral rating and set a $1.00 price target (down from $6.00) on shares of Lyell Immunopharma in a research note on Thursday.

Lyell Immunopharma Stock Performance

Shares of NASDAQ:LYEL opened at $1.45 on Thursday. The firm has a fifty day moving average of $2.39 and a 200 day moving average of $2.24. Lyell Immunopharma has a 52-week low of $1.18 and a 52-week high of $3.41. The firm has a market capitalization of $369.66 million, a PE ratio of -1.61 and a beta of -0.40.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. On average, sell-side analysts forecast that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC bought a new position in Lyell Immunopharma during the 4th quarter worth approximately $31,000. RPO LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter worth $38,000. Public Employees Retirement System of Ohio boosted its position in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after buying an additional 14,229 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Lyell Immunopharma by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after acquiring an additional 22,701 shares during the last quarter. Finally, Simplicity Wealth LLC purchased a new position in shares of Lyell Immunopharma in the first quarter valued at about $58,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.